PE20140214A1 - 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores kcnq2/3 - Google Patents

2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores kcnq2/3

Info

Publication number
PE20140214A1
PE20140214A1 PE2013000317A PE2013000317A PE20140214A1 PE 20140214 A1 PE20140214 A1 PE 20140214A1 PE 2013000317 A PE2013000317 A PE 2013000317A PE 2013000317 A PE2013000317 A PE 2013000317A PE 20140214 A1 PE20140214 A1 PE 20140214A1
Authority
PE
Peru
Prior art keywords
oxo
thioxo
kcnq2
dihydroquinoline
modulators
Prior art date
Application number
PE2013000317A
Other languages
English (en)
Inventor
Sven Kuhnert
George Bahrengerg
Achim Kless
Wolfgang Schroder
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20140214A1 publication Critical patent/PE20140214A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-OXO- Y 2-TIOXO-DIHIDROQUINOLINA-3-CARBOXAMIDAS SUSTITUIDOS DE FORMULA (I) DONDE X ES O U S; R1 ES UN RESIDUO ALIFATICO(C1-C10), CICLOALIFATICO(C3-C10), ENTRE OTROS; R2 ES F, Cl, CN, CF3, ENTRE OTROS; R3, R4, R5 Y R6 SON CADA UNO H, F, C(=O)H, C(=O)-OH, SCF3, NO2, ENTRE OTROS; R7 ES UN RESIDUO ALIFATICO(C1-C10), CICLOALIFATICO(C3-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: AMIDA DEL ACIDO N-[(3-FLUOROFENILO)-METILO]-1,4-DIMETILO-2-OXO-7-(TRIFLUOROMETILO)-1H-QUINOLINA-3-CARBOXILICO; AMIDA DE ACIDO 1-BUTILO-N-[(3-FLUOROFENILO)-METILO]-4-METILO-2-OXO-7-(TRIFLUOROMETILO)-1H-QUINOLINA-3-CARBOXILICO; AMIDA DE ACIDO N-[(3-FLUOROFENILO)-METILO]-1,4-DIMETILO-2-TIOXO-7-(TRIFLUOROMETILO)-1H-QUINOLINA-3-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS CANALES KCNQ2/3 K+ SIENDO UTILES EN EL TRATAMIENTO DE DOLOR AGUDO, DOLOR NEUROPATICO, DOLOR MUSCULAR, ANSIEDAD
PE2013000317A 2010-08-27 2011-08-26 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores kcnq2/3 PE20140214A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10008920 2010-08-27

Publications (1)

Publication Number Publication Date
PE20140214A1 true PE20140214A1 (es) 2014-02-19

Family

ID=43304979

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000317A PE20140214A1 (es) 2010-08-27 2011-08-26 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores kcnq2/3

Country Status (30)

Country Link
US (1) US8653102B2 (es)
EP (1) EP2609086B1 (es)
JP (1) JP5837934B2 (es)
KR (1) KR101983979B1 (es)
CN (1) CN103189357B (es)
AR (1) AR082731A1 (es)
AU (1) AU2011295408B2 (es)
BR (1) BR112013004690A2 (es)
CA (1) CA2809287C (es)
CL (1) CL2013000542A1 (es)
CO (1) CO6700825A2 (es)
CY (1) CY1116158T1 (es)
DK (1) DK2609086T3 (es)
EC (1) ECSP13012460A (es)
ES (1) ES2537615T3 (es)
HK (1) HK1185346A1 (es)
HR (1) HRP20150520T1 (es)
HU (1) HUE024870T2 (es)
IL (1) IL223820A (es)
MX (1) MX342459B (es)
NZ (1) NZ608697A (es)
PE (1) PE20140214A1 (es)
PL (1) PL2609086T3 (es)
PT (1) PT2609086E (es)
RS (1) RS54002B1 (es)
RU (1) RU2581362C2 (es)
SI (1) SI2609086T1 (es)
TW (1) TWI552750B (es)
WO (1) WO2012025239A1 (es)
ZA (1) ZA201302265B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653101B2 (en) * 2010-08-27 2014-02-18 Gruenenthal Gmbh Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators
JP2016502503A (ja) * 2012-10-11 2016-01-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｔｓｐｏ媒介性疾患および／または障害の治療および／または予防
WO2017120355A1 (en) * 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
BR112019014814B1 (pt) * 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2482596A1 (fr) 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
DE3111934A1 (de) 1981-03-26 1982-10-07 Bayer Ag, 5090 Leverkusen Oel-in-wasser-emulsionen, verfahren zu deren herstellung und deren verwendung
FR2509728A1 (fr) 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
DE3210063A1 (de) 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DE3211934A1 (de) 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
US5359365A (en) 1991-05-24 1994-10-25 Canon Kabushiki Kaisha Moving image processing method and apparatus
US5525611A (en) 1993-06-04 1996-06-11 Behforouz; Mohammad Lavendamycin analogs and methods of making and using them
US6030983A (en) 1993-06-04 2000-02-29 Ball State University Lavendamycin analogs, quinoline-5,8-diones and methods of using them
ATE188377T1 (de) 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
JPH08337583A (ja) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
GB9807114D0 (en) 1998-04-02 1998-06-03 Smithkline Beecham Plc Novel process
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
EP1200086A4 (en) 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
DE60037321D1 (de) 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
RS51019B (sr) 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
ES2330719T3 (es) * 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
JP2005508833A (ja) 2001-02-20 2005-04-07 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネル・モジュレーターとしての２，４−ジ置換ピリミジン−５−カルボキサミド誘導体
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
JP2004526756A (ja) 2001-04-06 2004-09-02 スミスクライン ビーチャム コーポレーション ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤
CA2499213A1 (en) 2002-09-17 2004-04-01 Pharmacia Corporation Aromatic liver x-receptor modulators
US7164021B2 (en) 2002-09-18 2007-01-16 The Curators Of The University Of Missouri Opiate analogs selective for the δ-opioid receptor
CA2505195C (en) 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones as potassium channel modulators
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
EP1604983A4 (en) 2003-03-17 2008-06-25 Takeda Pharmaceutical Receptor Antagonists
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005049608A1 (en) * 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
AR048669A1 (es) 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
WO2005105733A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
MX2007010547A (es) 2005-03-03 2007-10-03 Lundbeck & Co As H Derivados de piridina sustituidos.
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE602006007012D1 (de) 2005-07-20 2009-07-09 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
JP2009507849A (ja) 2005-09-09 2009-02-26 ブリストル−マイヤーズ スクイブ カンパニー 非環状ＩＫｕｒインヒビター
WO2007057447A1 (en) 2005-11-18 2007-05-24 Neurosearch A/S Novel quinazoline derivatives and their medical use
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
EP2012871A4 (en) 2006-04-13 2015-07-22 Nupathe Inc TRANSDERMAL PROCEDURES AND SYSTEMS FOR THE RELEASE OF ANTIMIGRAINE COMPOUNDS
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
EP2024272A4 (en) 2006-05-10 2010-11-17 Renovis Inc AMID DERIVATIVES AS ION CHANNEL NIGANDS, AND PHARMACEUTICAL COMPOSITIONS AND USER METHOD THEREFOR
US8134004B2 (en) 2006-07-11 2012-03-13 Pfizer Inc. Substituted N-bicyclicalkyl bicycliccarboxyamide compounds
EP2057133B1 (en) 2006-07-20 2014-08-20 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
WO2008127274A2 (en) 2006-09-22 2008-10-23 Ptc Therapeutics, Inc. Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
JP2010512305A (ja) 2006-10-23 2010-04-22 ファイザー株式会社 置換フェニルメチルビシクロカルボキシアミド化合物
US20080221161A1 (en) 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
US9162984B2 (en) 2007-03-30 2015-10-20 University Of Rochester Small-molecule modulators of melanin expression
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
WO2009052078A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
US8119656B2 (en) * 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2009298877A1 (en) 2008-09-23 2010-04-08 Georgetown University Viral and fungal inhibitors
AU2009306722A1 (en) 2008-10-24 2010-04-29 Grunenthal Gmbh Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 modulators for treating pain, epilepsy and urinary incontinence
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
MX2011008825A (es) 2009-03-10 2011-09-21 Gruenenthal Gmbh 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US8653101B2 (en) * 2010-08-27 2014-02-18 Gruenenthal Gmbh Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators
EP2609085A1 (en) 2010-08-27 2013-07-03 Grünenthal GmbH Substituted quinoline-3-carboxamides as kcnq2/3 modulators

Also Published As

Publication number Publication date
HK1185346A1 (en) 2014-02-14
ZA201302265B (en) 2021-05-26
RU2013113301A (ru) 2014-10-10
WO2012025239A1 (en) 2012-03-01
HUE024870T2 (en) 2016-02-29
ECSP13012460A (es) 2013-03-28
PT2609086E (pt) 2015-06-30
SI2609086T1 (sl) 2015-04-30
CL2013000542A1 (es) 2013-08-09
BR112013004690A2 (pt) 2016-05-10
NZ608697A (en) 2014-07-25
JP2013536213A (ja) 2013-09-19
ES2537615T3 (es) 2015-06-10
US8653102B2 (en) 2014-02-18
CA2809287A1 (en) 2012-03-01
TW201212917A (en) 2012-04-01
PL2609086T3 (pl) 2015-07-31
EP2609086A1 (en) 2013-07-03
AU2011295408B2 (en) 2015-05-14
TWI552750B (zh) 2016-10-11
RU2581362C2 (ru) 2016-04-20
CN103189357A (zh) 2013-07-03
KR20130095755A (ko) 2013-08-28
MX2013002119A (es) 2013-04-03
MX342459B (es) 2016-09-29
DK2609086T3 (da) 2015-03-30
CN103189357B (zh) 2015-11-25
AU2011295408A1 (en) 2013-04-11
CO6700825A2 (es) 2013-06-28
RS54002B1 (en) 2015-10-30
IL223820A (en) 2016-08-31
EP2609086B1 (en) 2015-02-25
CY1116158T1 (el) 2017-02-08
US20120053206A1 (en) 2012-03-01
KR101983979B1 (ko) 2019-05-30
CA2809287C (en) 2018-05-22
JP5837934B2 (ja) 2015-12-24
HRP20150520T1 (hr) 2015-07-03
AR082731A1 (es) 2012-12-26

Similar Documents

Publication Publication Date Title
PE20140199A1 (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20120780A1 (es) Nicotinamida sustituida como moduladores kcnq2/3
PE20131379A1 (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores kcnq2/3
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
PE20131350A1 (es) Compuestos sustituidos de benzamida
MA32534B1 (fr) Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1
PE20140836A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
PE20130339A1 (es) Compuestos heterociclicos y sus usos
PE20150403A1 (es) Pirrol carboxamidas fluorometilo sustituidas
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20071227A1 (es) Compuestos derivados de indazol como moduladores del receptor de glucocorticoides
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
PE20120374A1 (es) Fenilureas y fenilamidas como ligandos del receptor de vanilloides
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
PE20080274A1 (es) Derivados de dioxo-alcanos y dioxo-alquenos sustituidos como moduladores del receptor vanilloide subtipo 1 (trpv1)
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20140214A1 (es) 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores kcnq2/3
PE20110833A1 (es) Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio
CL2011001428A1 (es) Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras.
MX2016008077A (es) Compuestos heterociclicos fusionados como moduladores del canal ionico.

Legal Events

Date Code Title Description
FG Grant, registration